When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans? L. S. FreedmanP. Workman Original Articles Pages: 95 - 103
Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug matabolism Sandor Kerpel-FroniusJaap VerweyHerbert M. Pinedo Original Articles Pages: 104 - 108
The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol S. Kerpel-FroniusV. Erdélyi-TóthB. Kanyár Original Articles Pages: 109 - 113
Flavone acetic acid: a nonlinear pharmacokinetic model Alain GouyetteDavid J. KerrMike Soukop Original Articles Pages: 114 - 119
Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog Joanne I. BrodfuehrerTracy J. WilkeGarth Powis Original Articles Pages: 120 - 125
Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor)oxidoreductase John J. SchlagerGarth Powis Original Articles Pages: 126 - 130
Variability of tumor response to chemotherapy II. Contribution of tumor heterogeneity L. Simpson-HerrenP. E. NokerS. D. Wagoner Original Articles Pages: 131 - 136
The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man V. SkalskiJ. RivasW. Feindel Original Articles Pages: 137 - 140
A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma — intensive two-phase chemotherapy Central Lymphoma GroupNicholas S. A. StuartAdrian V. Simmons Original Articles Pages: 141 - 146
Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate Brenda J. FosterKaren R. GrotzingerThomas C. Hamilton Original Articles Pages: 147 - 152
The hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats T. DucastelleG. Raguenez-ViotteJ. P. Fillastre Original Articles Pages: 153 - 162
Correction of altered plasma membrane potentials Bharathi VayuvegulaLewis SlaterSudhir Gupta Original Articles Pages: 163 - 168
HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma R. LiangD. ToddT. K. Chan Original Articles Pages: 169 - 171
Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer Francesco BoccardoAndrea DecensiLuciano Giuliani Original Articles Pages: 172 - 174
Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites P. O. UadiaA. H. BlairT. Ghose Short Communication Pages: 175 - 177
Potentiation of cis-diamminedichloroplatinum nephrotoxicity by amikacin in rats Hermina T. M. JongejanAbraham P. ProvoostJan C. Molenaar Short Communication Pages: 178 - 180
Potentiation of anticoagulant effect of coumadin by 5-bromo-2′-deoxyuridine (BUDR) Sharon E. OsterH. Jeffrey Lawrence Letter to the Editors Pages: 181 - 181
